In Vivo Platform Melior Discovery offers a proprietary high-throughput in vivo phenotypic screening platform (theraTRACE) that spans up to 40 disease models across 14 therapeutic areas, enabling rapid indication discovery and risk de-risking for pharma and biotech partners.

Diverse Model Library With over 150 validated rat and mouse models across CNS, metabolic, inflammation, dermatology, and GI areas, Melior can tailor in vivo studies to specific client needs and accelerate target validation and lead optimization.

Repurposing Capability Specialization in drug repositioning (repurposing) offers a pathway to extend existing assets’ lifecycle, potentially opening collaborations with partners seeking new indications or faster development timelines.

Partnership Proven History of collaborations with both startups and global pharma (including Rett Syndrome Trust and Visikol) demonstrates a track record of flexible partnerships and expanding use cases, highlighting potential co-development and sponsored research opportunities.

Strategic Fit Financial scale and positioning (revenue in the low single digits with moderate funding) combined with recognized CRO credentials position Melior as a candidate for tiered service expansions, long-term CRO partnerships, and potentially strategic sales targeting mid-market biotechs and specialty pharma seeking robust in vivo efficacy assessment.